News & Events

Learn about what's new with CMC Biologics

AGC Biologics to Participate in Boston’s BIO International Convention

News

 

BOTHELL, Wash. – May 30, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate in the upcoming BIO International Convention in Boston, Mass. on June 4-7, 2018.

AGC Biologics Cleared for Commercial Manufacture of Portola's FDA-Approved Andexxa®

News

Drug Substance produced in AGC Biologics' facility in Bothell, Washington 

BOTHELL, Wash. – May 24, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that it will supply bulk drug substance for the launch of Portola Pharmaceuticals' Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

AGC Biologics enters into Commercial Supply Agreement with MacroGenics

News

BOTHELL, Wash. -- May 10, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that in late 2017 it entered into a commercial supply agreement with MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, for the manufacture of margetuximab, a clinical-stage, novel immune-optimized monoclonal antibody.

AGC Biologics enters into Commercial Manufacturing Agreement with Horizon Pharma plc

News

Manufacture of teprotumumab for treatment of thyroid eye disease
 

COPENHAGEN, DK -- May 3, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today it has entered into an agreement with Horizon Pharma plc for commercial supply of teprotumumab, a monoclonal antibody biologic for the treatment of moderate-to-severe active thyroid eye disease (TED).

BIO International Convention 2018, June 4-7, Boston, MA

Events

We're looking forward to this year's BIO International Convention in Boston, MA! Don't miss the AGC Biologics booth #663.

OutsourcedPharma East, May 14-15, Boston, MA

Events

Will you be in Boston this May for the OutsourcedPharma East Conference? Be sure to stop by Booth #123!

BIO Korea 2018, May 9-11, COEX, Seoul, South Korea

Events

Join us at the 2018 BIO Korea International Conference!
We'll be at Booth e48.  Let's talk about AGC Biologics' expanded capabilities across the globe, and how we can collaborate on your next challenge.

Polyvac® Peanut CMO appointed

News

Allergy Therapeutics prepares for manufacturing and clinical development of Polyvac ® Peanut allergy product

- Specialist CMO AGC Biologics engaged -

AGC Biologics Appoints New Site Head/General Manager of Bothell, WA Operations

News

Jin Wang, Ph.D. named Site Head/General Manager

 

BOTHELL, Wash. – April 12, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment of Dr. Jin Wang as Site Head/General Manager of its Bothell, Washington operations. Ms. Wang will provide leadership and site management to ensure AGC Biologics’ continued execution of world class contract development and manufacturing services. Dr. Wang will report to Patricio Massera, Chief Operations Officer.

CPhI North America, April 24-26, Philadelphia

Events

Headed to CPhI North America?
Stop by AGC Biologics booth #1701!

Follow Us
Join us on LinkedIn Follow us on Twitter